Biblio

Qureshy Z, Li H, Zeng Y, Rivera J, Cheng N, Peterson CN, Kim M-O, Ryan WR, Ha PK, Bauman JE et al..  2022.  STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.. Clin Cancer Res. 28(21):4737-4746.

Xu MJue, Plonowska KA, Gurman ZR, Humphrey AK, Ha PK, Wang SJ, El-Sayed IH, Heaton CM, George JR, Yom SS et al..  2020.  Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer.. Laryngoscope. 130(2):E48-E56.

Plonowska KA, Strohl MP, Wang SJ, Ha PK, George JR, Heaton CM, El-Sayed IH, St Clair JMallen-, Ryan WR.  2019.  Human Papillomavirus-Associated Oropharyngeal Cancer: Patterns of Nodal Disease.. Otolaryngol Head Neck Surg. 160(3):502-509.

Windon MJ, D'Souza G, Rettig EM, Westra WH, van Zante A, Wang SJ, Ryan WR, Mydlarz WK, Ha PK, Miles BA et al..  2018.  Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults.. Cancer. 124(14):2993-2999.

Yin LX, D'Souza G, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig EM, Ryan WR, Ha PK, Wentz A et al..  2018.  Prognostic factors for human papillomavirus-positive and negative oropharyngeal carcinomas.. Laryngoscope. 128(8):E287-E295.

Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, Yin LX, Ryan WR, Ha PK, Wentz A et al..  2017.  The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.. Cancer. 123(9):1566-1575.